August 13, 2022

Medical Trend

Medical News and Medical Resources

Israel: Myocarditis in young men may be related to Pfizer’s COVID-19 vaccine

Israel claims that myocarditis in some young men may be related to Pfizer’s COVID-19 vaccine



 

 

Israel: Myocarditis in young men may be related to Pfizer’s COVID-19 vaccine.  The Israeli Ministry of Health said late on Tuesday that some young men developed heart inflammation after the second dose of Pfizer -BioNTech SE COVID-19 vaccine. Ministry of Health officials discovered that this may be related to the vaccination.

 

Expert interpretation: Pfizer vaccine is 94% effective in the real world?  The effective rate of the COVID-19 vaccine jointly developed by Pfizer and BioNTech in the real world is expected to reach 94%, which is consistent with the data in the Phase III clinical trial. In addition, the effective rate of single injection of the vaccine can reach 57% after 14 days. This is Pfizer Vaccine's first real-world research data in the world.

 

More than 5 million people in Israel have been vaccinated with this vaccine, and the number of COVID-19 cases has dropped significantly. The Israeli Ministry of Health said on Wednesday that despite the above-mentioned association, it will expand the use of Pfizer’s vaccine to people aged 12-16 years. Earlier, the US Food and Drug Administration approved the authorization for use in this age group.

According to an investigation conducted by officials of the Israeli Ministry of Health, between the start of the vaccine program in December 2020 and May 2021, 275 cases of myocarditis occurred, of which 148 cases occurred within one month after vaccination. Among them, 27 cases appeared after the first dose of vaccination, and 121 cases appeared after the second dose of vaccination; about half of the patients had underlying diseases.

Pfizer said in a statement that currently, there is still no evidence that these cases were caused by vaccination. The company said that myocarditis is generally caused by a viral infection, and there have been reports that infection with the new coronavirus can cause this condition. BioNTech responded that more than 300 million doses of Pfizer/BioNTech’s COVID-19 vaccine have been vaccinated globally, and the benefits of the vaccine outweigh the risks.

“The report is being carefully evaluated and no conclusions have been reached yet,” the company pointed out. “The company and regulatory authorities continue to regularly and thoroughly evaluate side effects including myocarditis and pericarditis.”

At 9:51 New York time, Pfizer rose 1% to $38.89, and BioNTech’s ADR rose 0.4% to $169.65.

The Israeli health department stated that most of the cases were young men, especially those aged 16-19. In most cases, patients are admitted to the hospital for treatment for no more than four days, and 95% of the cases are classified as mild.

“The risk of contracting the new coronavirus is greater than the risk of vaccination,” said the country’s Ministry of Health. The number of patients with myocarditis is very small, and in most cases, patients can fully recover.

 

(source:internet, reference only)


Disclaimer of medicaltrend.org